Global Stents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Stents Market Size

• The global stents market size was valued atUSD 13.77 billion in 2024and is expected to reachUSD 21.50 billion by 2032, at aCAGR of 5.73%during the forecast period
• This growth is driven by factors such as the increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in stent design, and increasing demand for minimally invasive surgeries

Stents Market Analysis

• Stents are medical devices used to support and open up blood vessels or other tubular structures within the body, primarily for cardiovascular, urological, and biliary procedures. They are crucial for managing conditions like coronary artery disease, peripheral artery disease, and urinary tract obstructions
• The demand for stents is significantly driven by factors such as the increasing prevalence of cardiovascular diseases, the aging global population, and advancements in stent materials and designs
• North America is expected to dominate the global stents market with a largest market share of 43.7%, due to its advanced healthcare infrastructure, high adoption of minimally invasive surgeries, and increasing number of coronary artery disease cases
• Asia-Pacific is expected to be the fastest growing region in the stents market during the forecast period due to the expanding healthcare access, rising prevalence of chronic diseases, and increasing medical tourism in countries like India and China
• Vascular stents segment is expected to dominate the market with a market share of 87.9% due to the prevalence of unhealthy and hectic lifestyles in the society. Sedentary routines, poor dietary choices, and increased stress levels have led to an alarming rise in lifestyle-related conditions, particularly cardiovascular diseases

Report Scope and Stents Market Segmentation

Stents Market Trends

"Advancements in Stent Technology & Minimally Invasive Procedures"

• One prominent trend in the global stents market is the continuous advancement in stent materials and designs, including drug-eluting stents (DES) and bioresorbable stents, which enhance patient outcomes and reduce complications
• These innovations improve the effectiveness of stent implantation by promoting faster healing, reducing restenosis (re-narrowing of blood vessels), and minimizing the need for repeat procedures
  • For instance, bioresorbable stents, which gradually dissolve in the body, are gaining attention for their potential to reduce long-term complications, particularly in coronary artery disease treatments
• These advancements are revolutionizing stent-based procedures, improving patient safety, and driving the demand for next-generation stent technologies in cardiovascular, urological, and peripheral artery disease treatments

Stents Market Dynamics

Driver

"Growing Prevalence of Cardiovascular Diseases"

• The increasing prevalence of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and heart attacks, is significantly driving the demand for stents worldwide
• As the global population ages, the incidence of cardiovascular conditions continues to rise, with older adults being more susceptible to heart-related diseases that often require stent implantation
• The growing number of people seeking treatment for cardiovascular issues is driving demand for stents, improving patient outcomes, and reducing the risks associated with heart surgeries

For instance,

• According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, responsible for an estimated 17.9 million deaths each year, highlighting the urgent need for effective treatments like stent implantation
• As a result of the rising prevalence of cardiovascular diseases, there is a significant increase in the demand for stents in coronary, peripheral, and other vascular interventions

Opportunity

"Integration of Advanced Materials & Technologies in Stent Design"

• The development and integration of advanced materials such as bioresorbable stents and drug-eluting stents (DES) presents significant opportunities for market growth. These innovations improve patient outcomes by reducing complications like restenosis and eliminating the need for long-term stent removal
• New technologies, including bioresorbable polymers and advanced coatings, allow stents to dissolve over time, minimizing the long-term risks associated with permanent implants and enhancing the overall effectiveness of vascular treatments

For instance,

• In 2024, a study published in The Lancet demonstrated that bioresorbable stents can significantly reduce the risk of late-stage complications in patients with coronary artery disease, further driving the demand for this next-generation technology
• The integration of these advanced materials and technologies offers a tremendous opportunity to improve the performance of stents, enhance patient safety, and expand the market across cardiovascular and peripheral artery disease treatments

Restraint/Challenge

"High Cost of Stent Implantation & Healthcare Affordability"

• The high cost of stents, particularly drug-eluting stents (DES) and bioresorbable stents, presents a significant challenge to the global stents market, particularly in developing regions where healthcare budgets are limited
• Stents, especially those with advanced coatings or drug-eluting features, can cost thousands of dollars, making it difficult for smaller hospitals, clinics, and healthcare providers to afford them or implement them on a large scale
• This financial barrier can limit the adoption of advanced stent technologies, forcing healthcare facilities to rely on traditional, less expensive alternatives, which may not provide the same level of treatment efficacy

For instance,

• In October 2024, a report by the World Health Organization (WHO) highlighted that high healthcare costs, including stent implantation procedures, are one of the key barriers to accessing advanced cardiovascular care in low- and middle-income countries, contributing to disparities in treatment quality
• As a result, such cost constraints can limit the overall growth of the stent market, particularly in regions with limited financial resources and healthcare infrastructure

Stents Market Scope

The market is segmented on the basis of product, type, material, and end user.

In 2025, the vascular stents is projected to dominate the market with a largest share in product segment

The vascular stents segment is expected to dominate the stents market with the largest share of 87.9% due to the prevalence of unhealthy and hectic lifestyles in the society. Sedentary routines, poor dietary choices, and increased stress levels have led to an alarming rise in lifestyle-related conditions, particularly cardiovascular diseases.

The metallic stents is expected to account for the largest share during the forecast period in material segment

In 2025, the metallic stents segment is expected to dominate the market with the largest market share of 61.3% due to their durability and structural integrity. They provide immediate structural support and help maintain vessel patency, which is crucial in life-threatening situations such as acute myocardial infarctions and severe peripheral artery disease. The reliability and predictability of metallic stents have made them a popular choice as a primary treatment option.

Stents Market Regional Analysis

“North America Holds the Largest Share in the Stents Market"

• North America dominates the global stents market with a largest market share of 43.7%, driven by advanced healthcare infrastructure, high adoption of cutting-edge medical technologies, and the strong presence of key market players
• The U.S. holds a significant share of 35.9%, due to the increasing prevalence of cardiovascular diseases, rising demand for minimally invasive surgeries, and continuous advancements in stent technology such as drug-eluting stents (DES) and bioresorbable stents
• The availability of well-established reimbursement policies, high healthcare spending, and ongoing investments in research & development by leading medical device companies further strengthen the market in the region
• Additionally, the increasing number of coronary artery disease cases, coupled with rising awareness about the benefits of stent implantation, is contributing to the expansion of the stent market in North America

“Asia-Pacific is Projected to Register the Highest CAGR in the Stents Market”

• The Asia-Pacific region is expected to witness the highest growth rate in the global stents market, driven by rapid expansion in healthcare infrastructure, increasing awareness of cardiovascular diseases, and rising surgical volumes
• Countries such as China, India, and Japan are emerging as key markets due to the growing aging population, which is more susceptible to cardiovascular conditions that often require stent implantation
• Japan, with its advanced medical technology and increasing number of cardiovascular surgeons, remains a crucial market for stents. The country continues to lead in the adoption of innovative stent technologies and minimally invasive procedures
• China and India, with their large populations and rising cases of heart diseases, are witnessing increased government and private sector investments in modern cardiovascular care. The growing presence of global medical device manufacturers and improving healthcare accessibility further contribute to market growth in the region

Stents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Abbott Laboratories(U.S.)
• Boston Scientific Corporation(U.S.)
• Medtronic plc(Ireland)
• Johnson & Johnson(U.S.)
• Terumo Corporation (Japan)
• B. Braun Melsungen AG(Germany)
• Stryker Corporation (U.S.)
• Cook Medical (U.S.)
• Cordis Corporation (U.S.)
• MicroPort Scientific Corporation (China)
• Medytox Inc. (South Korea)
• Biotronik SE & Co. KG (Germany)
• AbbVie Inc. (U.S.)
• Medinex (France)
• Vascular Solutions Inc. (U.S.)
• AngioDynamics Inc. (U.S.)
• STENTYS S.A. (France)
• Sahajanand Medical Technologies Pvt. Ltd. (India)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• ZhuHai Lema Pharmaceutical Co., Ltd. (China)

Latest Developments in Global Stents Market

• In September 2024, Translumina Therapeutics, a leading provider of coronary stents, officially launched operations in the UAE. In partnership with the esteemed German Heart Centre, the company has introduced advanced drug-eluting stent technologies, including the world’s most extensively studied DES, supported by over a decade of comprehensive safety and efficacy research. This strategic collaboration not only strengthens Translumina’s global footprint but also contributes significantly to the ongoing growth and innovation within the global stents market, advancing the availability and effectiveness of cardiovascular treatments worldwide
• In July 2024, MicroPort Scientific Corporation announced that its subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., had received market approval from the National Medical Products Administration (NMPA) for Firesorb, the first next-generation fully bioresorbable cardiac stent. Pre-market studies demonstrated that Firesorb performed on par with permanent drug-eluting stents in key clinical outcomes, such as success rates and late lumen loss. Firesorb’s introduction is poised to contribute significantly to the global stents market, advancing the development of bioresorbable stents and offering an alternative with improved patient outcomes, while supporting the ongoing growth of minimally invasive cardiovascular treatments worldwide
• In May 2024, Abbott introduced the XIENCE Sierra, a new coronary stent system in India, specifically designed to treat patients with blocked arteries. As an extension of the XIENCE family, this innovative stent system provides enhanced safety for complex cardiac cases. The launch of XIENCE Sierra strengthens Abbott’s position in the global stents market, contributing to the growing demand for high-performance stents that offer improved outcomes, particularly in challenging cardiac conditions
• In May 2022, Abbott announced the launch of XIENCE Skypoint, the only drug-eluting stents (DES) approved in the U.S. designed to enable physicians to deliver advanced technology to patients with larger blood vessels. This innovative stent system enhances treatment options for patients with complex cardiovascular conditions. Abbott’s continued innovation in stent technology contributes significantly to the global stents market, addressing the growing demand for specialized solutions that improve clinical outcomes, particularly in cases involving larger arterial vessels
• In January 2022, Cook Medical announced that it had received FDA Breakthrough Designation for its drug-eluting stent intended for below-the-knee use. This designation recognizes the potential of the stent to address significant unmet clinical needs in treating peripheral artery disease. Cook Medical’s innovation in this area contributes to the global stents market by expanding treatment options for patients with challenging lower extremity conditions, driving the growth of specialized stent technologies, and improving patient outcomes in vascular interventions worldwide

SKU-1387